Media

Fusion Pharmaceuticals Licenses Isogenica’s CIS Display Technology

By April 18, 2018 9 Comments

Technology will be used to progress Fusion’s pipeline of targeted alpha therapeutics for the treatment of cancers

Cambridge, UK and Hamilton, Canada, 18th April 2018: Isogenica Ltd and Fusion Pharmaceuticals Inc (Fusion) today announced a new licensing agreement that will leverage each other’s strengths in recombinant protein technologies and radiopharmaceutical development. Isogenica is a leader in the design and construction of highly diverse synthetic antibody libraries and the use of novel in vitro polypeptide display systems. Fusion is a biopharmaceutical company focused on developing novel targeted alpha therapeutics, or radiopharmaceuticals, for the treatment of cancers.

Under the terms of the agreement, Isogenica has granted a licence to Fusion to utilise its proprietary in vitro CIS Display technology, for the discovery, development and commercialisation of therapeutic products derived from polypeptide libraries generated using this technology. Fusion will use the Isogenica technology to advance its internally developed drug pipeline. Under the terms of the agreement, Isogenica will receive an upfront fee and annual licence payments. If therapeutic products are advanced into development, Isogenica is entitled to additional milestone payments.

Adam Collier, Isogenica’s Director of Commercial Development commented: “This is another very significant deal for Isogenica, which highlights the robustness and utility of the company’s CIS Display technology as an excellent starting point for the rapid and efficient discovery of novel biotherapeutics. We look forward to working closely with Fusion to help their exciting drug discovery strategy to progress.

We are looking forward to the partnership with Isogenica,” said Eric Burak, Fusion’s CSO. “As part of our long-term strategy, Fusion is committed to both identifying our own agents and in-licensing assets that can be transformed into targeted alpha therapeutics. This partnership with Isogenica will help us to advance our internally developed pipeline of drugs while we progress our lead product, FPX-01, into the clinic later this year.”

 

About Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario, Canada and Boston, MA, focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01 with a clinical trial planned for 2018, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships.

 

About Isogenica Ltd

Isogenica is a drug discovery platform-licensing company focusing on the design and build of diverse, fully synthetic, antibody libraries for use in biopharmaceutical discovery. Partners can access an advanced camelid single-domain antibody library (llamdA™) and state-of-the-art, fully synthetic and highly diverse human Fab antibody libraries (Alexandria™). The company uses its proprietary Colibra™ library technology to ensure that the libraries very accurately reflect its advanced designs. Libraries can be screened in various formats, including phage and CIS Display, a proprietary in vitro display technology which maintains the high diversity of the llamdA™ libraries through the discovery process. CIS Display is also available as a stand-alone polypeptide display technology.

 

Contacts

Fusion Pharmaceuticals
Lynn Wick
info@fusionpharma.com

Join the discussion 9 Comments

  • Loyd Sission says:

    Thanks for all your efforts that you have put in this. very interesting info .

  • Hello! I could have sworn I’ve been to this blog before but after browsing through some of the post I realized it’s new to me. Anyways, I’m definitely happy I found it and I’ll be book-marking and checking back frequently!

  • Lucius Bejil says:

    Wow that was odd. I just wrote an very long comment but after I clicked submit my comment didn’t show up. Grrrr… well I’m not writing all that over again. Anyways, just wanted to say excellent blog!

  • You are a very bright person!

  • boekhouder says:

    Whats up this is kinda of off topic but I was wondering if blogs use
    WYSIWYG editors or if you have to manually code with HTML.
    I’m starting a blog soon but have no coding knowledge so I wanted to get guidance from someone with experience.

    Any help would be enormously appreciated!

  • DMC5 says:

    I’m impressed, I have to admit. Rarely do I encounter a blog that’s equally educative and engaging, and without a doubt, you have hit the nail on the head. The problem is something which not enough people are speaking intelligently about. Now i’m very happy that I stumbled across this during my hunt for something regarding this.

  • This web page may be a walk-through like the data you wanted concerning this and didn’t know who need to. Glimpse here, and you’ll certainly discover it.

  • resell proxy says:

    Thanks for your submission. Another item is that being photographer will involve not only difficulty in recording award-winning photographs but in addition hardships in acquiring the best digicam suited to your requirements and most especially hardships in maintaining the caliber of your camera. This really is very true and obvious for those photography lovers that are in capturing the particular nature’s exciting scenes — the mountains, the particular forests, the wild or even the seas. Going to these daring places absolutely requires a photographic camera that can meet the wild’s severe surroundings.

  • Wow, that’s what I was searching for, what a material! existing here at this blog, thanks admin of
    this site.

Leave a Reply